By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Biogen Idec, Inc. (North Carolina) 

5000 Davis Drive

Research Triangle Park  North Carolina  27709-4627  U.S.A.
Phone: 919-993-1100 Fax: 919-941-1112


SEARCH JOBS
Biogen Idec (NASDAQ: BIIB) is a biotechnology leader that discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hemophilia and autoimmune disorders. With its rich scientific heritage and passionate commitment to pioneering new advances, Biogen Idec recognizes that cutting-edge science and medicines can address unmet patient needs to change the course of devastating diseases.

Founded in 1978, Biogen Idec is the world’s oldest independent biotechnology company. Patients worldwide benefit from its leading multiple sclerosis therapies, and the company generates nearly $5 billion in annual revenues. Biogen Idec has a strong late stage pipeline with the potential to launch new products for multiple sclerosis, amyotrophic lateral sclerosis (ALS) and hemophilia by 2015.

With about 4,800 employees worldwide, Biogen Idec is a truly global organization. In addition to our headquarters in Weston, Mass., and our research operations in Cambridge, Mass., we have a world-class manufacturing facility in North Carolina and offices in Canada, Australia, Japan and throughout Europe. We also have a direct commercial presence in more than 29 markets and a network of distribution partners in more than 70 additional markets, including new markets such as Central/Eastern Europe, Brazil, China and India.

For product labeling, press releases and additional information about the company, please visit www.biogenidec.com


Key Statistics


Email:
Ownership: Public

Web Site: Biogen Idec, Inc. (North Carolina)
Employees: 1700
Symbol: BIIB
 



Industry
Biotechnology


Collaborations

NeoGenesis Pharmaceuticals, Inc.  Small molecule High Throughput Screening for multiple programs (6/01)

GPC Biotech, Inc.  HIV TAT-derived transport polytptides and methods of their use (5/01) - this was an outlicense from a research

ICOS Corporation  LFA-1 small molecule for psoriasis (7/01)

Elan Corporation PLC  (crohn's & MS)





Company News
Biogen Idec, Inc. (North Carolina) (BIIB), Eisai Inc. (ESALF.PK) Team Up at Research Triangle Park Facilities 12/12/2012 7:11:51 AM
Biogen Idec, Inc. (North Carolina) (BIIB) Opens New RTP Facility 11/30/2012 11:49:15 AM
Swedish Orphan Biovitrum's Agreement With Biogen Idec, Inc. (Massachusetts) (BIIB) Regarding Long-Lasting rFVIIIFc and rFIXFc Hemophilia Programs 2/6/2012 6:36:43 AM
Biogen Idec, Inc. (North Carolina) (BIIB) and Swedish Orphan Biovitrum AB Announce Decision to Advance Long- Lasting Hemophilia A Therapy into a Registrational Trial 7/9/2010 10:02:54 AM
US Judge Finds Biogen, Inc. Breached Pact with Biogen (JOBS) 9/4/2009 7:02:17 AM
Elan Corporation PLC (ELN)'s Tysabri May Reverse MS Damage, Shares Up 4/29/2009 7:28:54 AM
Biogen Idec, Inc. (Massachusetts) (BIIB) 1st-Quarter Earnings Up But Sales Disappoint 4/17/2009 7:18:55 AM
Bristol-Myers Squibb Company (BMY) (JOBS), Biogen Idec, Inc. (Massachusetts) (BIIB) (JOBS) CEOs: We're Not Rushing to Be Acquired 4/10/2009 7:29:42 AM
Biogen Idec, Inc. (Massachusetts) (BIIB) CEO Gets 7 Percent 2008 Compensation Boost 4/2/2009 7:16:21 AM
AVEO Pharmaceuticals, Inc. and Biogen Idec, Inc. (Massachusetts) (BIIB) Form Strategic Alliance for Development and Commercialization of ErbB3-Targeted Antibodies 3/24/2009 7:25:25 AM
12345678910...
//-->